viewReNeuron Group PLC

ReNeuron's Michael Hunt says key focus now is to build dataset for retinal disease study

ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott on the back of its results for the year to the end of March 2020. He says one of the main highlights has been the continuation of the retinal disease clinical study in the US. A recent update showed the treatment to have a “meaningful effect” for all points measured up to 18 months. Hunt adds that one of the key priorities in the year ahead is to build the dataset in that study as it's important for them to continue to show duration of effect at hopefully a higher dose level. ''If we're successful in doing that then that will set us up well for license deals and exploring the greater potential of those hRPC cells''.

Quick facts: ReNeuron Group PLC

Price: 83.31 GBX

Market: LSE
Market Cap: £26.56 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...



ReNeuron Group PLC: Proactive One2One Virtual Conference

ReNeuron Group PLC's (LON:RENE) Michael Hunt presents at the Proactive One2One Virtual Conference. ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

on 29/8/20

2 min read